Companies Veracyte, Inc

Veracyte (VCYT): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Veracyte, Inc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$7,421,877CEO Marc Stapley · source

Say-on-pay support97.4%Latest vote · source

CEO vs. named peers32nd pct.Of 19 peer CEOs

CEO pay ratio38:1To the median employee · source

CEO pay, last three years

$7,184,634FY2023
$6,816,368FY2024
$7,421,877FY2025

CEO total pay was $7,421,877 in fiscal 2025, up from $6,816,368 in fiscal 2024.

FY2025: salary $700,000 · bonus $0 · stock awards $5,890,877 · option awards $0

Executives and directors

John Leite · CCO Phillip Febbo · Executive Rebecca Chambers · CFO Annie McGuire · General Counsel Marc Stapley · CEO Brent Shafer · Independent Director Eliav Barr · Independent Director Evan Jones · Independent Director Jens Holstein · Independent Director Karin Eastham · Independent Director Muna Bhanji · Independent Director Robert S. Epstein · Chair of the Board Tom Miller · Independent Director

Frequently asked questions

Who was the highest-paid executive at Veracyte, Inc in fiscal 2025?

As disclosed, Marc Stapley (Chief Executive Officer) was the highest-paid executive at Veracyte, Inc in fiscal 2025, with total compensation of $7,421,877.

How does Veracyte, Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Marc Stapley's total compensation ranked at the 32nd percentile of Veracyte, Inc's disclosed peer group.

What is Veracyte, Inc's CEO-to-median employee pay ratio?

As disclosed, Veracyte, Inc's CEO-to-median employee pay ratio was 38:1.

How did shareholders vote on Veracyte, Inc's executive compensation?

As disclosed, 97.4% of shareholders supported Veracyte, Inc's executive compensation in the latest say-on-pay vote.

How much does Veracyte, Inc spend in total on board compensation for fiscal 2025?

As disclosed, Veracyte, Inc reported total board compensation of $2,564,912 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Marc Stapley	$700,000	$0	$5,890,877	$0	$826,000	$0	$5,000	$7,421,877
Chief Executive Officer
John Leite	510,300	0	2,356,325	0	331,185	0	5,000	3,202,810
Global Chief Commercial Officer
Rebecca Chambers	550,000	0	1,963,604	0	356,950	0	5,000	2,875,554
Chief Financial Officer
Annie McGuire	500,000	0	1,963,604	0	324,500	0	5,000	2,793,104
General Counsel and Head of Market Access
Phillip Febbo	561,000	0	1,570,883	0	364,089	0	5,000	2,500,972
Chief Scientific Officer and Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Marc Stapley	$7,421,877	$6,816,368	$7,184,634	↑ +605,509
John Leite	3,202,810	3,093,951	1,924,469	↑ +108,859
Rebecca Chambers	2,875,554	3,645,346	2,778,584	↓ −769,792
Annie McGuire	2,793,104	3,090,848	2,481,118	↓ −297,744
Phillip Febbo	2,500,972	2,789,661	3,787,041	↓ −288,689

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

We have designed our executive compensation program to reward our executive officers, including our NEOs, at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain and motivate them to exert their best efforts in the highly competitive environment in which we operate.

CEO STI target (% of salary)	100%
CEO LTI target (% of salary)	—
Independent consultant	Aon
Clawback policy	True
Anti-hedging	True
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Annie McGuire	RSU	2025-03-06	—	—	30,200	—	$981,802
Marc Stapley	RSU	2025-03-06	—	—	90,601	—	2,945,439
Marc Stapley	PSU	2025-03-06	61,156	90,601	—	135,902	2,945,439
Phillip Febbo	RSU	2025-03-06	—	—	24,160	—	785,442
John Leite	PSU	2025-03-06	24,462	36,240	—	54,360	1,178,162
Phillip Febbo	PSU	2025-03-06	16,308	24,160	—	36,240	785,442
Annie McGuire	PSU	2025-03-06	20,385	30,200	—	45,300	981,802
Rebecca Chambers	RSU	2025-03-06	—	—	30,200	—	981,802
Rebecca Chambers	PSU	2025-03-06	20,385	30,200	—	45,300	981,802
John Leite	RSU	2025-03-06	—	—	36,240	—	1,178,162

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Annie McGuire	$981,802	$981,802	$0	50.0%
Marc Stapley	2,945,439	2,945,439	0	50.0%
Phillip Febbo	785,442	785,442	0	50.0%
John Leite	1,178,162	1,178,162	0	50.0%
Rebecca Chambers	981,802	981,802	0	50.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Rebecca Chambers	RSU	1,296	—	$54,562
Annie McGuire	RSU	1,429	—	60,161
Annie McGuire	Option	1,758	27.8	—
Rebecca Chambers	Option	2,361	26.02	—
Marc Stapley	RSU	3,534	—	148,781
John Leite	RSU	4,819	—	202,880
John Leite	RSU	4,928	—	207,469
Marc Stapley	Option	6,440	26.02	—
John Leite	Option	7,897	23.73	—
John Leite	Option	8,071	19.81	—
Annie McGuire	Option	12,082	23.73	—
Rebecca Chambers	Option	13,424	23.73	—
John Leite	RSU	17,221	—	725,004
Phillip Febbo	PSU	17,957	—	755,990
John Leite	PSU	22,446	—	944,977
Annie McGuire	PSU	22,446	—	944,977
Rebecca Chambers	PSU	22,650	—	953,565
Phillip Febbo	RSU	24,160	—	1,017,136
Phillip Febbo	PSU	24,160	—	1,017,136
Rebecca Chambers	PSU	26,936	—	1,134,006
Annie McGuire	RSU	28,388	—	1,195,135
Rebecca Chambers	RSU	30,200	—	1,271,420
Annie McGuire	RSU	30,200	—	1,271,420
Annie McGuire	PSU	30,200	—	1,271,420
Rebecca Chambers	RSU	31,541	—	1,327,876
John Leite	RSU	36,240	—	1,525,704
John Leite	PSU	36,240	—	1,525,704
Phillip Febbo	Option	39,352	21.96	—
Marc Stapley	Option	40,272	23.73	—
Phillip Febbo	RSU	46,388	—	1,952,935
Marc Stapley	PSU	51,626	—	2,173,455
John Leite	RSU	57,985	—	2,441,169
Annie McGuire	RSU	57,985	—	2,441,169
Rebecca Chambers	RSU	69,581	—	2,929,360
Phillip Febbo	RSU	74,455	—	3,134,556
Marc Stapley	RSU	90,601	—	3,814,302
Marc Stapley	PSU	90,601	—	3,814,302
Marc Stapley	RSU	94,628	—	3,983,839
Marc Stapley	RSU	133,368	—	5,614,793

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Robert S. EpsteinIndependent · Board Chair · Nominating and Corporate Governance (Chair)	$110,000	$249,989	$0	—	$0	$359,989
Jens HolsteinIndependent · Audit (Chair) · Compensation	77,500	249,989	0	—	0	327,489
Karin EasthamIndependent · Compensation (Chair) · Audit	75,000	249,989	0	—	0	324,989
Evan JonesIndependent · Regulatory and Compliance (Chair) · Audit · Nominating and Corporate Governance	75,000	249,989	0	—	0	324,989
Muna BhanjiIndependent · Nominating and Corporate Governance · Regulatory and Compliance	60,000	249,989	0	—	0	309,989
Brent ShaferIndependent · Compensation	57,500	249,989	0	—	0	307,489
Eliav BarrIndependent · Regulatory and Compliance	55,000	249,989	0	—	0	304,989
Tom MillerIndependent · Regulatory and Compliance	55,000	249,989	0	—	0	304,989
Marc StapleyEmployee director	0	0	0	—	0	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$250,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 10,000
Stock ownership guideline	Appropriate stock ownership requirements for all executives and non-executive directors

Total cost of the board

Component	FY2025
Cash retainers and fees	$565,000
Equity awards (grant-date value)	$1,999,912
All other compensation	$0
Total cost of the board	$2,564,912

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Veracyte as a peer

Companies that benchmark against VCYT

22 companies name VCYT as a compensation peer

The list of companies that name VCYT as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

TXG 10x GenomicsCDNA CareDXCTKB Cytek BiosciencesFLGT Fulgent GeneticsGH Guardant HealthMRVI Maravai LifesciencesMYGN Myriad GeneticsNTRA NateraPACB Pacific Biosciences of CaliforniaTWST Twist BioscienceRARE Ultragenyx PharmaceuticalVCEL VericelGKOS GlaukosADPT Adaptive BiotechnologiesBCRX BioCryst PharmaceuticalsNEO NeoGenomicsNVRO NevroEXAS Exact SciencesFOLD Amicus Therapeutics

Peer reciprocity

The companies Veracyte, Inc names as compensation peers that name it back in their own disclosed peer groups.

10x Genomics (TXG)¹⁰⁸CareDX (CDNA)¹⁰⁹Cytek Biosciences (CTKB)¹¹⁰Fulgent Genetics (FLGT)¹¹¹Maravai Lifesciences (MRVI)¹¹²Pacific Biosciences of California (PACB)¹¹³Adaptive Biotechnologies (ADPT)¹¹⁴NeoGenomics (NEO)¹¹⁵

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exact Sciences	2024	Kevin Conroy	$1,083,368	$13,496,138	$0	$712,329	$15,539,378
2	Natera	2025	Steven Chapman	853,710	12,979,558	0	1,114,151	14,957,319
3	Twist Bioscience	2025	Emily Leproust	720,000	11,998,134	0	932,918	13,781,570
4	BioCryst Pharmaceuticals	2025	Jon Stonehouse	728,466	0	11,132,458	1,052,633	12,951,082
5	Glaukos	2025	Thomas Burns	850,000	7,649,947	3,527,497	0	12,034,087
6	Nevro	2023	Kevin Thornal	515,625	10,080,173	0	402,750	11,453,548
7	Ultragenyx Pharmaceutical	2025	Emil Kakkis	861,100	8,364,938	1,847,356	299,663	11,405,535
8	Vericel	2025	Dominick Colangelo	860,000	3,964,630	5,456,287	860,000	11,156,368
9	Maravai Lifesciences	2025	Bernd Brust	388,863	7,660,000	1,460,000	425,343	10,129,708
10	NeoGenomics	2025	Tony Zook	601,539	3,999,997	3,998,235	513,400	9,127,092
11	Adaptive Biotechnologies	2025	Chad Robins	698,258	7,675,100	0	703,380	9,081,690
12	Guardant Health	2025	AmirAli Talasaz	1	8,647,709	0	0	8,661,227
13	Amicus Therapeutics	2024	Bradley Campbell	767,308	4,990,365	2,105,627	0	8,526,943
14	Veracyte, Inc	2025	Marc Stapley	700,000	5,890,877	0	826,000	7,421,877
15	CareDX	2025	John Hanna	693,269	5,622,638	0	852,515	7,179,699
16	10x Genomics	2025	Serge Saxonov	674,250	5,020,269	0	634,725	6,329,244
17	Fulgent Genetics	2025	Ming Hsieh	1,000,000	4,000,000	0	1,207,000	6,207,000
18	Myriad Genetics	2025	Samraat Raha	856,901	3,989,729	0	814,660	5,686,740
19	Cytek Biosciences	2025	Wenbin Jiang	620,000	2,000,000	2,000,000	485,211	5,120,061
20	Pacific Biosciences of California	2025	Christian Henry	748,250	1,151,013	1,696,278	714,305	4,309,846

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Veracyte, Inc	118%	PSU 50 · RSU 50	No	Aon
10x Genomics	93%	PSU 60 · RSU 40	Yes — 3-year Relative TSR	Alpine Rewards LLC
Adaptive Biotechnologies	not disclosed	RSU 50 · PSU 50	not disclosed	Semler Brossy Consulting Group, LLC
Amicus Therapeutics	not disclosed	Option 33 · RSU 33 · PRSU 33	Yes — TSR Goal	Pay Governance
BioCryst Pharmaceuticals	not disclosed	not disclosed	not disclosed	Aon
CareDX	not disclosed	RSU 70 · PRSU 30	No	Alpine Rewards
Cytek Biosciences	78.4%	RSU 50 · Options 50	not disclosed	Meridian Compensation Partners, LLC
Exact Sciences	47%	PSU 60 · RSU 40	No	Aon
Fulgent Genetics	120.7%	PSU 60 · RSU 40	No	USI
Glaukos	not disclosed	RSU 50 · PRSU 50	No	Frederic W. Cook & Co., Inc.
Guardant Health	140%	PSU 50 · RSU 50 · Option 35	No	Aon
Maravai Lifesciences	not disclosed	not disclosed	No	Meridian Compensation Partners, LLC
Myriad Genetics	89%	RSU 50 · PSU 50	Yes	Mercer, LLC
Natera	131.1%	PSU 50 · RSU 50	No	Aon
NeoGenomics	60%	RSU 50 · Options 50	not disclosed	WTW
Nevro	53.7%	not disclosed	No	Aon
Pacific Biosciences of California	95%	not disclosed	not disclosed	Aon Human Capital Solutions
Twist Bioscience	129.6%	PSU 50 · RSU 50	No	not disclosed
Ultragenyx Pharmaceutical	44%	PSU 60 · RSU 20 · Options 20	Yes — Relative TSR	Aon's Human Capital Solutions Practice
Vericel	100%	Options 58 · RSU 42	not disclosed	FW Cook

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-10	71,266,771	1,858,805	43,634	97.4%	Passed
2025	2025-06-17	67,829,470	1,849,211	11,545	97.33%	Passed
2024	2024-06-12	64,610,097	3,179,578	54,526	95.23%	Passed
2022	2022-06-15	59,077,731	5,356,352	19,681	91.66%	Passed
2021	2021-06-07	55,705,774	4,601,097	69,697	92.26%	Passed
2020	2020-06-05	39,733,134	1,228,494	337,291	96.21%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-10	97.4%^a
2025	2025-06-17	97.33%^b
2024	2024-06-12	95.23%^c

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "AGAINST" this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes "AGAINST" this proposal.”.

c. Approved under the standard stated in the filing — “3, the approval, on a non-binding advisory basis, of the compensation of our named executive officers, you may vote "FOR," vote "AGAINST" or "ABSTAIN." Abstentions have the same effect as votes "AGAINST" this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	38 : 1
CEO total compensation	$7,421,877
Median employee compensation	$196,646

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Annie McGuire	SVP, General Counsel	2026-05-06	D	5,102	$38	$194,131	Common	Form 4 ↗
Annie McGuire	SVP, General Counsel	2026-05-06	D	5,102	40	204,080	Common	Form 4 ↗
Robert S. Epstein	Director	2026-05-20	D	10,000	44	440,129	Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-05-22	D	24,000	0	0	Derivative, Class A Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-05-22	D	24,000	45	1,089,624	Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-05-22	A	24,000	25	595,200	Common	Form 4 ↗
Marc Stapley	Director	2026-06-02	D	9,012	48	430,774	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-06-02	D	3,693	48	176,525	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-06-02	D	3,292	48	157,358	Common	Form 4 ↗
Phillip Febbo	Chief Scientific & Med Officer	2026-06-02	D	3,730	48	178,294	Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-06-02	D	1,361	48	65,056	Common	Form 4 ↗
John Leite	Global Chief Commercial Off	2026-06-02	D	4,059	48	194,020	Common	Form 4 ↗
Marc Stapley	Director	2026-06-04	D	138,051	0	0	Derivative, Class A Common	Form 4 ↗
Marc Stapley	Director	2026-06-04	D	138,051	50	6,919,585	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-06-04	D	1,961	50	98,229	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-06-04	D	1,600	49	78,854	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-06-04	D	1,776	50	89,007	Common	Form 4 ↗
John Leite	Global Chief Commercial Off	2026-06-04	D	13,975	50	699,732	Common	Form 4 ↗
Marc Stapley	Director	2026-06-04	A	138,051	37	5,052,667	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-06-04	D	1,400	49	69,029	Common	Form 4 ↗
Brent Shafer	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Karin Eastham	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Muna Bhanji	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Evan Jones	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Jens Holstein	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Tom Miller	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Robert S. Epstein	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Eliav Barr	Director	2026-06-11	A	5,272	0	0	Common	Form 4 ↗
Karin Eastham	Director	2026-06-18	D	529	54	28,328	Common	Form 4 ↗
Karin Eastham	Director	2026-06-18	D	3,200	53	168,906	Common	Form 4 ↗
Muna Bhanji	Director	2026-09-01	D	1,864	43	80,096	Common	Form 4 ↗
Marc Stapley	Director	2026-09-02	D	8,782	45	394,136	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-09-02	D	3,603	45	161,703	Common	Form 4 ↗
Phillip Febbo	Chief Scientific & Med Officer	2026-09-02	D	3,639	45	163,318	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-09-02	D	3,215	45	144,289	Common	Form 4 ↗
John Leite	Global Chief Commercial Off	2026-09-02	D	3,961	45	177,770	Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-09-02	D	1,361	45	61,082	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-09-04	D	1,100	44	48,039	Common	Form 4 ↗
Annie McGuire	EVP, General Counsel	2026-09-04	D	2,154	43	92,173	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-09-04	D	1,175	44	51,364	Common	Form 4 ↗
Phillip Febbo	Chief Scientific & Med Officer	2026-09-04	D	10,405	43	446,305	Common	Form 4 ↗
Rebecca Chambers	Chief Financial Officer	2026-09-04	D	2,477	43	106,030	Common	Form 4 ↗
Phillip Febbo	Chief Scientific & Med Officer	2026-09-04	D	2,705	44	118,105	Common	Form 4 ↗
Jens Holstein	Director	2026-09-14	D	5,000	41	204,747	Common	Form 4 ↗
John Leite	Global Chief Commercial Off	2026-09-21	D	4,015	40	160,600	Common	Form 4 ↗
Jens Holstein	Director	2026-09-24	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Jens Holstein	Director	2026-09-24	D	7,500	47	352,500	Common	Form 4 ↗
Jens Holstein	Director	2026-09-24	A	7,500	35	264,750	Common	Form 4 ↗
Muna Bhanji	Director	2026-10-19	D	1,864	44	81,457	Common	Form 4 ↗
Karin Eastham	Director	2026-10-27	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Karin Eastham	Director	2026-10-27	D	14,850	50	742,573	Common	Form 4 ↗
Jens Holstein	Director	2026-10-27	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Jens Holstein	Director	2026-10-27	D	7,500	50	375,000	Common	Form 4 ↗
Jens Holstein	Director	2026-10-27	A	7,500	35	264,750	Common	Form 4 ↗
Karin Eastham	Director	2026-10-27	A	10,000	27	270,100	Common	Form 4 ↗
Jonathan Wygant	VP, Chief Accounting Officer	2026-10-28	D	1,306	50	65,705	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (115 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Marc Stapley. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 59. As printed: 7,421,877. View filing ↗
Section 01, John Leite. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 3,202,810. View filing ↗
Section 01, Rebecca Chambers. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 2,875,554. View filing ↗
Section 01, Annie McGuire. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 2,793,104. View filing ↗
Section 01, Phillip Febbo. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 2,500,972. View filing ↗
Section 03, Annie McGuire RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Marc Stapley RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Marc Stapley PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Phillip Febbo RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Leite PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Phillip Febbo PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Annie McGuire PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Rebecca Chambers RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Rebecca Chambers PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Leite RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: 38 : 1. View filing ↗
Section 08, Robert S. Epstein. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 359,989. View filing ↗
Section 08, Jens Holstein. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 327,489. View filing ↗
Section 08, Karin Eastham. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 324,989. View filing ↗
Section 08, Evan Jones. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 324,989. View filing ↗
Section 08, Muna Bhanji. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 309,989. View filing ↗
Section 08, Brent Shafer. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 307,489. View filing ↗
Section 08, Eliav Barr. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 304,989. View filing ↗
Section 08, Tom Miller. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 304,989. View filing ↗
Section 08, Marc Stapley. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Annie McGuire 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Robert S. Epstein 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marc Stapley 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Phillip Febbo 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Leite 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marc Stapley 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marc Stapley 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Leite 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marc Stapley 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Brent Shafer 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Muna Bhanji 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Evan Jones 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Tom Miller 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Robert S. Epstein 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Eliav Barr 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Muna Bhanji 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marc Stapley 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Phillip Febbo 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Leite 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Annie McGuire 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Phillip Febbo 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rebecca Chambers 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Phillip Febbo 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Leite 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-09-24. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-09-24. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-09-24. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Muna Bhanji 2026-10-19. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jens Holstein 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Karin Eastham 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Wygant 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 97.4% (votes for as printed: 71,266,771). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 97.33% (votes for as printed: 67,829,470). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 64,610,097). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 565,000 + equity 1,999,912 + all other 0 = 2,564,912, summed across the director compensation table rows.
Exact Sciences, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. View filing ↗
Natera, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. View filing ↗
Twist Bioscience, Section 10b CEO total. DEF 14A, filed 2026-01-06. CEO total compensation as printed in Twist Bioscience's own proxy. As printed: 13,781,570. View filing ↗
BioCryst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. View filing ↗
Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
Ultragenyx Pharmaceutical, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. View filing ↗
Vericel, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. View filing ↗
Maravai Lifesciences, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai Lifesciences's own proxy. As printed: 10,129,708. View filing ↗
NeoGenomics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics's own proxy. As printed: 9,127,092. View filing ↗
Adaptive Biotechnologies, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies's own proxy. As printed: 9,081,690. View filing ↗
Guardant Health, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health's own proxy. As printed: 8,661,227. View filing ↗
Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
Veracyte, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc's own proxy. As printed: 7,421,877. View filing ↗
CareDX, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDX's own proxy. As printed: 7,179,699. View filing ↗
10x Genomics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in 10x Genomics's own proxy. As printed: 6,329,244. View filing ↗
Fulgent Genetics, Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Fulgent Genetics's own proxy. As printed: 6,207,000. View filing ↗
Myriad Genetics, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics's own proxy. As printed: 5,686,740. View filing ↗
Cytek Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cytek Biosciences's own proxy. As printed: 5,120,061. View filing ↗
Pacific Biosciences of California, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. View filing ↗
Section 10a, 10x Genomics reciprocity. DEF 14A. 10x Genomics names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, CareDX reciprocity. DEF 14A. CareDX names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Cytek Biosciences reciprocity. DEF 14A. Cytek Biosciences names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Fulgent Genetics reciprocity. DEF 14A. Fulgent Genetics names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Maravai Lifesciences reciprocity. DEF 14A. Maravai Lifesciences names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Pacific Biosciences of California reciprocity. DEF 14A. Pacific Biosciences of California names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Adaptive Biotechnologies reciprocity. DEF 14A. Adaptive Biotechnologies names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, NeoGenomics reciprocity. DEF 14A. NeoGenomics names Veracyte, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗